Table 3.

Effect of long-term treatments on the risk of recurrences after the index thrombosis in the entire patient cohort (multivariable analysis).

	Overall recurrent thromboses (HR, 95% CI)		Arterial recurrent thrombosis (HR, 95% CI)*	p	Venous recurrent thrombosis (HR, 95% CI)*	p
Age > 60 years	1.23 (0.99–1.52)	0.06	1.18 (0.89–1.57)	0.23	1.28 (0.91–1.79)	0.15
Male sex	0.94 (0.76–1.17)	0.60	0.97 (0.73–1.28)	0.99	0.91 (0.65–1.28)	0.61
Antiplatelet treatment	0.58 (0.43–0.79)	0.0005	0.54 (0.35–0.82)	0.003	0.64 (0.40–1.03)	0.07
Oral anticoagulation (VKA or DOACs)	0.58 (0.41–0.81)	0.001	0.58 (0.35–0.96)	0.03	0.60 (0.37–0.95)	0.03
Hydroxyurea	0.75 (0.57–1.00)	0.05	0.67 (0.46–0.98)	0.04	0.87 (0.56–1.33)	0.52
Cytoreduction with agents other than hydroxyurea#	1.04 (0.74–1.45)	0.80	0.94 (0.61–1.46)	0.80	1.22 (0.72–2.04)	0.44

HR hazard ratio

*Multivariable analysis adjusted for the arterial or venous site of the first thrombosis

^#Anagrelide, interferon, pipobroman, busulfan, and ruxolitinib

Bold values are those with statistical significance